Trials / Completed
CompletedNCT01775358
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Aileron Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of a single dose of ALRN-5281 administered by subcutaneous injection to healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALRN-5281 0.015 mg/kg | |
| DRUG | ALRN-5281 0.05 mg/kg | |
| DRUG | ALRN-5281 0.15 mg/kg | |
| DRUG | Placebo 0.015 mg/kg | |
| DRUG | Placebo 0.05mg/kg | |
| DRUG | Placebo 0.15mg/kg |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2013-01-25
- Last updated
- 2013-05-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01775358. Inclusion in this directory is not an endorsement.